POMDOCTOR LIMITED filed a report describing progress in its strategic partnerships with leading domestic pharmaceutical companies to grow its internet hospital business in China. The Company plans to make these collaborations a core part of its long-term strategy to expand online hospital operations and improve profitability.
The filing highlights rapid growth in China’s online pharmaceutical market, with online drug sales rising from approximately RMB 19 billion in 2020 to about RMB 60.8 billion in 2023 and RMB 71.8 billion (approximately US$10.3 billion) in 2024, a compound annual growth rate of 39.4%. Pomdoctor, through its subsidiaries, has entered into sales and purchase agreements with several listed and innovative drug makers, enabling access to innovative and patented products on its platforms and securing purchase discounts, rebates, and incentives tied to sales targets.
The Company describes this model as a way for pharmaceutical firms to gain better channel control and more efficient marketing, while Pomdoctor benefits from direct sourcing, quality assurance, and pricing advantages. It views this flattened, digital, patient-centric supply chain collaboration as aligned with China’s healthcare reforms and as a key direction for the evolution of pharmaceutical distribution.